Overview
AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis
Status:
Completed
Completed
Trial end date:
2014-12-20
2014-12-20
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study will evaluate the safety and efficacy of AGN-229666 for the prevention of allergen-mediated conjunctivitis.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
AllerganTreatments:
Olopatadine Hydrochloride
Ophthalmic Solutions
Criteria
Inclusion Criteria:-Japanese patients living in Japan with a history of allergic conjunctivitis.
Exclusion Criteria:
- Presence of active eye infection (bacterial, viral, or fungal)
- History of an eye herpetic infection.